Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo.
Eradication of Staphylococcus aureus biofilms after rifampin treatment was tested in a mouse model of device-related infection by using biophotonic imaging. Following treatment, the bioluminescent signals decreased to undetectable levels, irrespective of the age of the biofilm. After the final treatment, the signals rebounded in a time-dependent manner and reached those for the untreated mice. Readministration of rifampin was unsuccessful in eradicating reestablished infections, with the rifampin MICs for such bacteria being increased and with the bacteria having point mutations in the rpoB gene.
Kadurugamuwa
Jagath L
JL
Xenogen Corporation, 860 Atlantic Ave., Alameda, CA 94501, USA. Jagath.Kadurugamuwa@Xenogen.com
Sin
Lin V
LV
Yu
Jun
J
Francis
Kevin P
KP
Purchio
Tony F
TF
Contag
Pamela R
PR
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects*; D015169:Colony Count, Microbial; D012321:DNA-Directed RNA Polymerases / Q000235:genetics; D003952:Diagnostic Imaging; D008163:Luminescent Measurements; D051379:Mice; D012293:Rifampin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics
D000904:Antibiotics, Antitubercular; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit; D012293:Rifampin